Sana Biotechnology, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Sana Biotechnology, Inc. (SANA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$59.92 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-08.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-08
- Sana Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$59.92M, a 6189.84% decline year-over-year.
- Sana Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was $984.00K.
- Sana Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$85.12M.
- Sana Biotechnology, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$72.47M, a 504.06% decline year-over-year.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month |
|---|---|---|---|
| 2024-09-30 | -$59.92M 10-Q · filed 2024-11-08 | -$217.69M 10-Q · filed 2024-11-08 | |
| 2023-09-30 | $984.00K 10-Q · filed 2024-11-08 | -$195.14M 10-Q · filed 2024-11-08 | |
| 2022-09-30 | -$85.12M 10-Q · filed 2023-11-08 | -$157.59M derived: sum of 2 quarters · filed 2023-11-08 | -$189.03M 10-Q · filed 2023-11-08 |
| 2022-06-30 | -$72.47M 10-Q · filed 2022-08-04 | -$103.91M 10-Q · filed 2022-08-04 | |
| 2021-06-30 | $17.93M 10-Q · filed 2022-08-04 | -$161.93M 10-Q · filed 2022-08-04 | |
| 2020-06-30 | -$87.81M 10-Q · filed 2021-08-04 | -$120.68M 10-Q · filed 2021-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |